NEW YORK (GenomeWeb News) – Marijn Dekkers has resigned his position as president, CEO, and member of the board of directors at Thermo Fisher Scientific to take over as CEO of German drug, chemicals, and life science giant Bayer.
Thermo Fisher has appointed current COO Marc Casper to become president, CEO, and board member effective Oct. 15, 2009.
Dekkers has been with Thermo Fisher for the past nine years, overseeing Thermo Electron's $10.6 billion merger with Fisher Scientific in late 2006.
Casper has been with Thermo as president of its life and laboratory sciences business since 2001. He served as president of the firm's analytical technologies businesses after the merger.
Thermo Fisher also reaffirmed its full-year 2009 outlook for revenues of between $9.8 billion and $10.1 billion, and adjusted earnings per share of between $2.85 and $3.10.
Though Dekkers is leaving Thermo Fisher now, he won't take the helm at Bayer until Oct. 1, 2010, when current CEO Wener Wenning steps down. However, Dekkers will serve as interim CEO of Bayer's healthcare division, taking over for Arthur Higgins, who is leaving "for personal reasons" in the first half of next year.
In early trade on the New York Stock Exchange, shares of Thermo Fisher were down 4 percent at $45.71.